【摘要】 目的 :检测不同亚型乳腺癌中E cadherin(E cad)表达情况 ,为临床制定治疗方案和判断预后提供依据。　方法 :运用组织芯片技术、免疫组织化学 (S P)法检测 4 8例乳腺癌 (其中浸润性导管癌 4 3例 ,浸润性小叶癌 4例 ,神经内分泌癌 1例 )E cad的表达情况 ,并与传统的常规病理学方法比较。　结果 :免疫组化标记 :4 3例浸润性导管癌E cad阳性表达者 37例 ,占 86 .0 % (37/ 4 3) ;4例浸润性小叶癌无一例E cad表达。对照组中 13例乳腺良性病变E cad均呈阳性表达。随访 :4 3例浸润性导管癌中 3例死亡 (7.0 % ) ;4例浸润性小叶癌中 2例死亡 (5 0 .0 % )。结论 :E cad可作为鉴别浸润性导管癌和浸润性小叶癌有价值的免疫标志物。组织芯片技术具有高信息量、简捷、快速、高效、成本低、重复性好等优点 ,在病理学领域中具有重要的实际意义和广阔的应用前景更多还原

【Abstract】 Objective: To evaluate the expression of E-cadherin in different subtypes of breast carcinoma, to give evidences for clinical therapy programs and judgment of prognosis. Methods:Tissue microarray technology and immunohistochemistry (S-P) methods were used to detect the expression of E-cadherin in 48 cases of breast carcinoma (consisting of 43 cases of invasive ductal carcinoma, 4 cases of invasive lobular carcinoma and 1 case of neuroendocrine carcinoma) respectively. The result was compared with the traditional pathological investigation. Thirteen cases of benign lesion of breast were used for comparison. Results: Forty-three cases of invasive ductal carcinoma and 4 cases of invasion lobular carcinoma of 48 cases of breast carcinoma were in 28～73 years (mean, 51.1 years). In 48 cases of breast carcinoma, 37 of 43 cases of invasive ductal carcinoma were E-cadherin positive, 86.0% (37/43) of all; none of 4 cases of invasive lobular carcinoma. Thirteen cases of benign lesion of breast expressed E-cadherin. Follow-up: 3 (7.0%) of 43 cases of invasive ductal carcinoma died; 2 (50.0%) of 4 cases of invasive lobular carcinoma died. Conclusion: E-cadherin can be used as an immunomarker to differentiate between invasive ductal carcinoma and invasive lobular carcinoma. Tissue microarray technology has the advantages of high-throughput, conciseness, rapidity, high efficiency, low cost, nice reproducibility, etc. It has important practical significance and broad application prospect in pathology.更多还原